NASDAQ$CTKB
Cytek Biosciences Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Third quarter revenue grew compared to prior year, gross margins, net income, and adjusted EBITDA improved.
Cytek Biosciences reported an 18% increase in total revenue for the third quarter of 2022, reaching $40.5 million. Gross profit margins, net income, and adjusted EBITDA also improved compared to the prior year quarter. The company expanded its installed base to 1,501 instruments, with 142 instrument placements during the quarter.
- Total revenue was $40.5 million for the third quarter, an 18% increase year-over-year.
- Gross profit margin was 66.4%, and adjusted gross profit margin was 68.4% for the third quarter, up from the prior year.
- Net income was $1.6 million for the third quarter, with adjusted EBITDA of $7.3 million.
- Installed base expanded to 1,501 instruments, with 142 instrument placements during the third quarter.
Headline financials
Revenue & EPS history
Cytek Biosciences · Revenue · Quarterly
$40.5M
Revenue by segment
Cytek Biosciences · $40.5M total across 2 segments · Q3 2022
- Product Revenue$36.4M—89.9%
- Service Revenue$4.09M—10.1%
Forward guidance
Cytek Biosciences continues to expect full year 2022 revenue to be closer to the high end of the range of $160 million to $168 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
-4.5%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+42.3%
Q3 2024
Best reaction
-23.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -18.4% | -17.2% | |
| Q4 2025 | +1.6% | +0.2% | -1.8% | |
| Q3 2025 | +2.6% | +21.5% | +27.6% | |
| Q1 2025 | -22.8% | -28.0% | -9.2% | |
| Q4 2024 | -6.7% | -7.1% | -16.8% | |
| Q3 2024 | +42.3% | +35.6% | +25.8% | |
| Q2 2024 | -12.7% | -10.5% | -6.7% | |
| Q1 2024 | -2.8% | -3.1% | -6.0% | |
| Q4 2023 | -13.0% | -8.2% | -12.9% | |
| Q3 2023 | +14.7% | +12.4% | +75.7% | |
| Q2 2023 | -2.0% | +2.4% | -25.1% | |
| Q1 2023 | -23.6% | -35.4% | -30.9% | |
| Q4 2022 | -10.0% | +0.7% | -15.5% | |
| Q3 2022 | -0.6% | +0.6% | -22.3% | |
| Q2 2022 | +1.0% | +1.9% | -4.0% | |
| Q1 2022 | +1.1% | +23.1% | +25.6% | |
| Q4 2021 | -1.9% | +1.3% | -26.5% | |
| Q3 2020 | +1.8% | -0.2% | -17.9% | |
| Q3 2021 | -0.9% | -4.4% | -19.0% | |
| Q2 2020 | -1.8% | +6.8% | -12.3% | |
| Q4 2020 | -1.8% | +6.8% | -12.3% | |
| Q2 2021 | +16.2% | +14.9% | +2.5% | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro